Spruce Total Current Liabilities vs Selling General Administrative Analysis

SPRB Stock

USD 0.55 0.02 3.77%

Spruce Biosciences financial indicator trend analysis is much more than just breaking down Spruce Biosciences prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Spruce Biosciences is a good investment. Please check the relationship between Spruce Biosciences Total Current Liabilities and its Selling General Administrative accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spruce Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Spruce Stock refer to our How to Trade Spruce Stock guide.

Total Current Liabilities vs Selling General Administrative

Total Current Liabilities vs Selling General Administrative Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Spruce Biosciences Total Current Liabilities account and Selling General Administrative. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Spruce Biosciences' Total Current Liabilities and Selling General Administrative is 0.81. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Selling General Administrative in the same time period over historical financial statements of Spruce Biosciences, assuming nothing else is changed. The correlation between historical values of Spruce Biosciences' Total Current Liabilities and Selling General Administrative is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of Spruce Biosciences are associated (or correlated) with its Selling General Administrative. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Selling General Administrative has no effect on the direction of Total Current Liabilities i.e., Spruce Biosciences' Total Current Liabilities and Selling General Administrative go up and down completely randomly.

Correlation Coefficient

0.81

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Total Current Liabilities

Total Current Liabilities is an item on Spruce Biosciences balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Spruce Biosciences are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Selling General Administrative

Most indicators from Spruce Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Spruce Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spruce Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Spruce Stock refer to our How to Trade Spruce Stock guide.The current year's Issuance Of Capital Stock is expected to grow to about 62.6 M, whereas Selling General Administrative is forecasted to decline to about 8.3 M.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	68K	74K	78K	49.3K
Total Operating Expenses	42.1M	47.3M	62.1M	37.4M

Reconciled Depreciation Total Operating Expenses

Spruce Biosciences fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Common Stock	Short Long Term Debt Total	Other Liab
Total Assets		0.68	0.69	1.0	1.0	-0.87	-0.72	0.65	0.89	0.51	0.24	0.44	0.99	0.48	0.8	-0.89	0.85	0.98	-0.59	1.0	0.99	0.82	0.99	0.82	0.86	0.82
Other Current Liab	0.68		0.99	0.65	0.64	-0.62	-0.99	0.36	0.56	0.19	0.32	0.31	0.67	0.89	0.85	-0.81	0.89	0.73	-0.22	0.65	0.68	0.9	0.63	0.9	0.6	0.86
Total Current Liabilities	0.69	0.99		0.66	0.65	-0.7	-0.96	0.48	0.64	0.13	0.19	0.17	0.7	0.82	0.85	-0.8	0.87	0.74	-0.19	0.66	0.71	0.86	0.66	0.86	0.57	0.84
Total Stockholder Equity	1.0	0.65	0.66		1.0	-0.86	-0.69	0.64	0.88	0.53	0.25	0.46	0.99	0.46	0.76	-0.9	0.83	0.98	-0.65	1.0	0.98	0.8	0.99	0.8	0.88	0.8
Net Tangible Assets	1.0	0.64	0.65	1.0		-0.86	-0.69	0.65	0.88	0.53	0.25	0.46	0.99	0.45	0.76	-0.9	0.83	0.98	-0.64	1.0	0.99	0.8	0.99	0.8	0.87	0.81
Net Debt	-0.87	-0.62	-0.7	-0.86	-0.86		0.61	-0.84	-0.98	-0.14	0.05	0.02	-0.92	-0.26	-0.7	0.78	-0.72	-0.9	0.45	-0.86	-0.91	-0.63	-0.91	-0.63	-0.64	-0.72
Retained Earnings	-0.72	-0.99	-0.96	-0.69	-0.69	0.61		-0.34	-0.57	-0.26	-0.39	-0.41	-0.71	-0.9	-0.88	0.84	-0.93	-0.76	0.24	-0.7	-0.72	-0.94	-0.67	-0.94	-0.65	-0.9
Accounts Payable	0.65	0.36	0.48	0.64	0.65	-0.84	-0.34		0.83	0.25	-0.51	-0.31	0.66	0.09	0.45	-0.56	0.43	0.64	-0.33	0.63	0.66	0.42	0.66	0.42	0.29	0.4
Cash	0.89	0.56	0.64	0.88	0.88	-0.98	-0.57	0.83		0.18	-0.01	0.03	0.93	0.21	0.71	-0.76	0.73	0.92	-0.43	0.88	0.93	0.64	0.93	0.64	0.62	0.74
Non Current Assets Total	0.51	0.19	0.13	0.53	0.53	-0.14	-0.26	0.25	0.18		-0.01	0.62	0.39	0.41	0.33	-0.38	0.3	0.37	-0.41	0.53	0.39	0.45	0.4	0.45	0.53	0.18
Non Currrent Assets Other	0.24	0.32	0.19	0.25	0.25	0.05	-0.39	-0.51	-0.01	-0.01		0.77	0.25	0.37	0.26	-0.35	0.45	0.3	-0.26	0.26	0.26	0.39	0.25	0.39	0.47	0.52
Other Assets	0.44	0.31	0.17	0.46	0.46	0.02	-0.41	-0.31	0.03	0.62	0.77		0.37	0.52	0.37	-0.43	0.48	0.4	-0.41	0.47	0.38	0.53	0.38	0.53	0.66	0.45
Cash And Short Term Investments	0.99	0.67	0.7	0.99	0.99	-0.92	-0.71	0.66	0.93	0.39	0.25	0.37		0.42	0.8	-0.89	0.85	1.0	-0.57	0.99	1.0	0.79	1.0	0.79	0.83	0.84
Common Stock Total Equity	0.48	0.89	0.82	0.46	0.45	-0.26	-0.9	0.09	0.21	0.41	0.37	0.52	0.42		0.69	-0.66	0.74	0.49	-0.16	0.46	0.44	0.84	0.38	0.84	0.51	0.68
Common Stock Shares Outstanding	0.8	0.85	0.85	0.76	0.76	-0.7	-0.88	0.45	0.71	0.33	0.26	0.37	0.8	0.69		-0.7	0.92	0.84	-0.05	0.77	0.81	0.9	0.76	0.9	0.61	0.88
Non Current Liabilities Total	-0.89	-0.81	-0.8	-0.9	-0.9	0.78	0.84	-0.56	-0.76	-0.38	-0.35	-0.43	-0.89	-0.66	-0.7		-0.88	-0.91	0.69	-0.9	-0.89	-0.87	-0.87	-0.87	-0.81	-0.87
Other Current Assets	0.85	0.89	0.87	0.83	0.83	-0.72	-0.93	0.43	0.73	0.3	0.45	0.48	0.85	0.74	0.92	-0.88		0.9	-0.31	0.83	0.86	0.97	0.82	0.97	0.69	0.99
Other Stockholder Equity	0.98	0.73	0.74	0.98	0.98	-0.9	-0.76	0.64	0.92	0.37	0.3	0.4	1.0	0.49	0.84	-0.91	0.9		-0.54	0.98	1.0	0.84	0.99	0.84	0.82	0.89
Total Liab	-0.59	-0.22	-0.19	-0.65	-0.64	0.45	0.24	-0.33	-0.43	-0.41	-0.26	-0.41	-0.57	-0.16	-0.05	0.69	-0.31	-0.54		-0.63	-0.56	-0.3	-0.61	-0.3	-0.73	-0.32
Net Invested Capital	1.0	0.65	0.66	1.0	1.0	-0.86	-0.7	0.63	0.88	0.53	0.26	0.47	0.99	0.46	0.77	-0.9	0.83	0.98	-0.63		0.99	0.8	0.99	0.8	0.88	0.81
Total Current Assets	0.99	0.68	0.71	0.98	0.99	-0.91	-0.72	0.66	0.93	0.39	0.26	0.38	1.0	0.44	0.81	-0.89	0.86	1.0	-0.56	0.99		0.8	1.0	0.8	0.83	0.85
Capital Stock	0.82	0.9	0.86	0.8	0.8	-0.63	-0.94	0.42	0.64	0.45	0.39	0.53	0.79	0.84	0.9	-0.87	0.97	0.84	-0.3	0.8	0.8		0.75	1.0	0.66	0.93
Net Working Capital	0.99	0.63	0.66	0.99	0.99	-0.91	-0.67	0.66	0.93	0.4	0.25	0.38	1.0	0.38	0.76	-0.87	0.82	0.99	-0.61	0.99	1.0	0.75		0.75	0.85	0.81
Common Stock	0.82	0.9	0.86	0.8	0.8	-0.63	-0.94	0.42	0.64	0.45	0.39	0.53	0.79	0.84	0.9	-0.87	0.97	0.84	-0.3	0.8	0.8	1.0	0.75		0.66	0.93
Short Long Term Debt Total	0.86	0.6	0.57	0.88	0.87	-0.64	-0.65	0.29	0.62	0.53	0.47	0.66	0.83	0.51	0.61	-0.81	0.69	0.82	-0.73	0.88	0.83	0.66	0.85	0.66		0.66
Other Liab	0.82	0.86	0.84	0.8	0.81	-0.72	-0.9	0.4	0.74	0.18	0.52	0.45	0.84	0.68	0.88	-0.87	0.99	0.89	-0.32	0.81	0.85	0.93	0.81	0.93	0.66

Click cells to compare fundamentals

Spruce Biosciences Account Relationship Matchups

Spruce Biosciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	4.7M	162.9M	126.5M	85.6M	103.9M	89.5M
Other Current Liab	1.2M	3.3M	5.7M	9.3M	14.3M	15.1M
Total Current Liabilities	4.3M	9.8M	8.9M	12.4M	24.5M	25.7M
Total Stockholder Equity	(30.6M)	149.4M	111.4M	68.5M	76.5M	65.5M
Net Tangible Assets	(30.6M)	149.4M	111.4M	68.5M	78.8M	61.8M
Net Debt	521K	(151.0M)	(36.6M)	(18.3M)	(91.7M)	(87.1M)
Retained Earnings	(31.3M)	(60.8M)	(103.1M)	(149.3M)	(197.2M)	(187.4M)
Accounts Payable	1.9M	3.6M	2.8M	1.4M	3.3M	2.8M
Cash	3.9M	157.2M	42.7M	24.5M	96.3M	60.3M
Non Current Assets Total	40K	2.5M	34.6M	2.0M	1.8M	1.7M
Non Currrent Assets Other	40K	477K	653K	55.2M	582K	552.9K
Other Assets	40K	2.5K	513K	640K	1.0	0.95
Cash And Short Term Investments	3.9M	157.2M	89.0M	79.1M	96.3M	78.8M
Common Stock Shares Outstanding	22.3M	23.3M	23.4M	23.5M	38.5M	24.9M
Liabilities And Stockholders Equity	4.7M	162.9M	126.5M	85.6M	103.9M	89.5M
Non Current Liabilities Total	31.0M	3.7M	6.2M	4.7M	3.0M	2.8M
Other Current Assets	513K	3.2M	2.9M	4.5M	5.8M	3.2M
Other Stockholder Equity	664K	373.1M	214.7M	218.4M	273.7M	198.2M
Total Liab	35.3M	13.5M	15.1M	17.2M	27.4M	17.5M
Net Invested Capital	(26.2M)	153.9M	116.2M	73.4M	79.8M	69.6M
Total Current Assets	4.7M	160.4M	91.9M	83.6M	102.2M	82.0M
Net Working Capital	349K	150.6M	83.0M	71.2M	77.7M	70.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

When determining whether Spruce Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Spruce Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Spruce Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Spruce Biosciences Stock:

How To Invest In Spruce

Details

Is Spruce Stock a good investment?

Details

What is Spruce Biosciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spruce Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Spruce Stock refer to our How to Trade Spruce Stock guide.

You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spruce Biosciences. If investors know Spruce will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spruce Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.95)

Revenue Per Share

0.173

Quarterly Revenue Growth

(0.80)

Return On Assets

(0.30)

Return On Equity

(0.58)

The market value of Spruce Biosciences is measured differently than its book value, which is the value of Spruce that is recorded on the company's balance sheet. Investors also form their own opinion of Spruce Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Spruce Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spruce Biosciences' market value can be influenced by many factors that don't directly affect Spruce Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Spruce Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spruce Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spruce Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Spruce Total Current Liabilities vs Selling General Administrative Analysis

Total Current Liabilities vs Selling General Administrative

Total Current Liabilities vs Selling General Administrative Correlation Analysis

Correlation Coefficient

Total Current Liabilities

Selling General Administrative

Spruce Biosciences fundamental ratios Correlations

Spruce Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Spruce Biosciences fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Net Tangible Assets	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Net Tangible Assets	+ 1.0	Total Stockholder Equity
Net Invested Capital	+ 1.0	Total Stockholder Equity
Net Invested Capital	+ 1.0	Net Tangible Assets

Retained Earnings	- 0.99	Other Current Liab
Cash	- 0.98	Net Debt
Retained Earnings	- 0.96	Total Current Liabilities
Common Stock	- 0.94	Retained Earnings
Capital Stock	- 0.94	Retained Earnings
Other Current Assets	- 0.93	Retained Earnings